Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (ανοίγει νέο παράθυρο)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Πηγή‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Καταχώριση‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (ανοίγει νέο παράθυρο)

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (ανοίγει νέο παράθυρο)

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Πηγή‎: Am J Hematol 2011;86(9):762-7.

Καταχώριση‎: PubMed 21850658

DOI‎: 10.1002/ajh.22111

https://www.ncbi.nlm.nih.gov/pubmed/21850658 (ανοίγει νέο παράθυρο)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (ανοίγει νέο παράθυρο)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Πηγή‎: Acta Haematol 2007;117(3):162-7.

Καταχώριση‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (ανοίγει νέο παράθυρο)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (ανοίγει νέο παράθυρο)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Πηγή‎: Am J Hematol 2013;88(12):990-6.

Καταχώριση‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (ανοίγει νέο παράθυρο)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (ανοίγει νέο παράθυρο)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Πηγή‎: J Clin Oncol 2011;29(28):3791-7.

Καταχώριση‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (ανοίγει νέο παράθυρο)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (ανοίγει νέο παράθυρο)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Πηγή‎: Cancer 2012;118(3):848-55.

Καταχώριση‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (ανοίγει νέο παράθυρο)

Management of anemia in cancer patients. (ανοίγει νέο παράθυρο)

Calabrich A, Katz A.

Πηγή‎: Future Oncol 2011;7(4):507-17.

Καταχώριση‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (ανοίγει νέο παράθυρο)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (ανοίγει νέο παράθυρο)

Chojnowski K, Trelinski J.

Πηγή‎: Acta Haematol Pol 2007;38(4):479-84.

Καταχώριση‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (ανοίγει νέο παράθυρο)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (ανοίγει νέο παράθυρο)

Deger M, Eisterer W, Kutikova L, Salek S.

Πηγή‎: Support Care Cancer 2013;21(2):485-93.

Καταχώριση‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (ανοίγει νέο παράθυρο)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (ανοίγει νέο παράθυρο)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Πηγή‎: BJU Int 2011;108(10):1582-7.

Καταχώριση‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (ανοίγει νέο παράθυρο)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (ανοίγει νέο παράθυρο)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Πηγή‎: J Clin Oncol 2010;28(13):2239-45.

Καταχώριση‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (ανοίγει νέο παράθυρο)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (ανοίγει νέο παράθυρο)

Ford PA, Grant SJ, Mick R, Keck G.

Πηγή‎: J Clin Oncol 2015;33(15):1674-9.

Καταχώριση‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (ανοίγει νέο παράθυρο)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (ανοίγει νέο παράθυρο)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Πηγή‎: Br J Cancer 2011;105(9):1267-72.

Καταχώριση‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (ανοίγει νέο παράθυρο)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (ανοίγει νέο παράθυρο)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Πηγή‎: J Intern Med 2017;281(3):284-99.

Καταχώριση‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (ανοίγει νέο παράθυρο)

How I treat cancer-associated anemia. (ανοίγει νέο παράθυρο)

Gilreath JA, Rodgers GM

Πηγή‎: Blood 2020;136(7):801-13.

Καταχώριση‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (ανοίγει νέο παράθυρο)

Update on safety of ESAs in cancer-induced anemia. (ανοίγει νέο παράθυρο)

Glaspy J.

Πηγή‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Καταχώριση‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (ανοίγει νέο παράθυρο)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (ανοίγει νέο παράθυρο)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Πηγή‎: Eur J Haematol. 2023 110(4):354-61.

Καταχώριση‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (ανοίγει νέο παράθυρο)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (ανοίγει νέο παράθυρο)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Πηγή‎: Int J Hematol 2015;102(4):401-12.

Καταχώριση‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (ανοίγει νέο παράθυρο)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (ανοίγει νέο παράθυρο)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Πηγή‎: Cancer 2013;119(1):107-14.

Καταχώριση‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (ανοίγει νέο παράθυρο)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (ανοίγει νέο παράθυρο)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Πηγή‎: J Natl Cancer Inst 2013;105(14):1018-26.

Καταχώριση‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (ανοίγει νέο παράθυρο)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (ανοίγει νέο παράθυρο)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Πηγή‎: Cancer Sci 2013;104(4):481-5.

Καταχώριση‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (ανοίγει νέο παράθυρο)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (ανοίγει νέο παράθυρο)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Πηγή‎: Br J Haematol 2019;184(2):134-60.

Καταχώριση‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (ανοίγει νέο παράθυρο)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (ανοίγει νέο παράθυρο)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Πηγή‎: Support Care Cancer 2012;20(1):159-65.

Καταχώριση‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (ανοίγει νέο παράθυρο)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (ανοίγει νέο παράθυρο)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Πηγή‎: Leuk Lymphoma. 2019;60(9):2324-7.

Καταχώριση‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (ανοίγει νέο παράθυρο)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (ανοίγει νέο παράθυρο)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Πηγή‎: Oncologist 2010;15(9):935-43.

Καταχώριση‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (ανοίγει νέο παράθυρο)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (ανοίγει νέο παράθυρο)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Πηγή‎: Lung Cancer 2012;76(3):478-85.

Καταχώριση‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (ανοίγει νέο παράθυρο)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (ανοίγει νέο παράθυρο)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Πηγή‎: Eur J Haematol 2016;97(1):33-8.

Καταχώριση‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (ανοίγει νέο παράθυρο)

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (ανοίγει νέο παράθυρο)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Πηγή‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Καταχώριση‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (ανοίγει νέο παράθυρο)

Intravenous iron in oncology. (ανοίγει νέο παράθυρο)

Auerbach M, Ballard H.

Πηγή‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Καταχώριση‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (ανοίγει νέο παράθυρο)

Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (ανοίγει νέο παράθυρο)

Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A

Πηγή‎: J Clin Med. 2022;11(14):4156.

Καταχώριση‎: PubMed 35887920

DOI‎: 10.3390/jcm11144156

https://pubmed.ncbi.nlm.nih.gov/35887920/ (ανοίγει νέο παράθυρο)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (ανοίγει νέο παράθυρο)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Πηγή‎: Int J Colorectal Dis 2016;31(3):543-51.

Καταχώριση‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (ανοίγει νέο παράθυρο)

How I treat cancer-associated anemia. (ανοίγει νέο παράθυρο)

Gilreath JA, Rodgers GM

Πηγή‎: Blood 2020;136(7):801-13.

Καταχώριση‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (ανοίγει νέο παράθυρο)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (ανοίγει νέο παράθυρο)

Gilreath JA, Stenehjem DD, Rodgers GM.

Πηγή‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Καταχώριση‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (ανοίγει νέο παράθυρο)

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (ανοίγει νέο παράθυρο)

Henry DH, Dahl NV, Auerbach MA.

Πηγή‎: Am J Hematol 2012;87(3):308-10.

Καταχώριση‎: PubMed 22262486

DOI‎: 10.1002/ajh.22262

https://www.ncbi.nlm.nih.gov/pubmed/22262486 (ανοίγει νέο παράθυρο)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (ανοίγει νέο παράθυρο)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Πηγή‎: Eur J Haematol. 2023 110(4):354-61.

Καταχώριση‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (ανοίγει νέο παράθυρο)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (ανοίγει νέο παράθυρο)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Πηγή‎: Curr Oncol. 2023 24;30(9):7836-51.

Καταχώριση‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (ανοίγει νέο παράθυρο)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (ανοίγει νέο παράθυρο)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Πηγή‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Καταχώριση‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (ανοίγει νέο παράθυρο)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (ανοίγει νέο παράθυρο)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Πηγή‎: World J Gastroenterol 2014;20(8):1972-85.

Καταχώριση‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (ανοίγει νέο παράθυρο)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (ανοίγει νέο παράθυρο)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Πηγή‎: South Asian J Cancer. 2023 15;12(2):93-9.

Καταχώριση‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (ανοίγει νέο παράθυρο)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (ανοίγει νέο παράθυρο)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Πηγή‎: J Clin Oncol 2008;26(10):1619-25.

Καταχώριση‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (ανοίγει νέο παράθυρο)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (ανοίγει νέο παράθυρο)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Πηγή‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Καταχώριση‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (ανοίγει νέο παράθυρο)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (ανοίγει νέο παράθυρο)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Πηγή‎: Ann Oncol 2013;24(2):475-82.

Καταχώριση‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (ανοίγει νέο παράθυρο)